The aim of this study is to investigate crosstalk between these two signalling axes as they share some common downstream signalling effectors and evaluate whether combination of PPARĪ³ agonist and an EGFR inhibitor may overcome resistance to EGFR therapy in bladder cancer.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}